Krystal Biotech Inc

The global regenerative medicine market is projected to reach approximately USD 162 billion by 2034, growing at a compound annual growth rate of around 16% from a 2025 size of about USD 41 billion, according to a report by DelveInsight. North America held the largest share at roughly 42% in 2025, driven by advanced healthcare infrastructure and strong R&D investment, while the Asia-Pacific region is expected to be one of the fastest-growing markets. Key companies in the space include Novartis AG, Gilead Sciences, Bristol-Myers Squibb, Johnson & Johnson, and Krystal Biotech, among others. Recent developments include the European Commission's approval of Krystal Biotech's gene therapy Vyjuvek in April 2025 and the U.S. FDA's approval of Abeona Therapeutics' Zevaskyn, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa. Growth is fueled by advances in stem cell and gene therapies, rising chronic disease prevalence, and supportive regulatory pathways.

Krystal Biotech reported higher second-quarter earnings, with net income rising to $54.77 million, or $1.79 per share, from $38.33 million, or $1.29 per share, in the same period last year. Revenue increased 24.1% to $119.22 million from $96.04 million a year earlier.

Krystal Biotech has been moved from the S&P 600 to the S&P 400, joining the S&P 400 Health Care and Biotechnology indices, and has filed a response with the U.S. Patent and Trademark Office that includes single-patient data from its investigational KB801 gene therapy for neurotrophic keratitis. The company noted that the observed complete closure of a persistent corneal epithelial defect in one KB801-treated patient came from a discontinued study, carries no safety concerns, and should not be used to draw conclusions on efficacy, emphasizing the early nature of the data and its relevance to ongoing patent protection efforts. The S&P 400 inclusion increases potential exposure to mid-cap index funds, though it mainly affects trading and ownership dynamics rather than fundamental clinical or reimbursement milestones. Krystal Biotech's investment narrative remains centered on VYJUVEK supporting a profitable rare disease franchise while the broader gene therapy pipeline gradually adds new revenue sources, with upcoming pivotal data and regulatory milestones as key near-term catalysts.

S&P Dow Jones Indices announced that Krystal Biotech will join the S&P MidCap 400, replacing Taylor Morrison Home before trading opens on July 24. The change follows Berkshire Hathaway's planned acquisition of Taylor Morrison Home, which is expected to close on or around that date. Tutor Perini will replace Krystal Biotech in the S&P SmallCap 600 on the same day. Separately, V2X will replace Avanos Medical in the S&P SmallCap 600 on July 27 after American Industrial Partners' acquisition of Avanos Medical closes.

The Brown Capital Management Small Company Fund added Krystal Biotech to its portfolio in the first quarter of 2026, highlighting the gene therapy company's durable and recession-resistant revenue stream. The fund noted that Krystal Biotech's lead product, VYJUVEK, is the first topical, re-dosable gene therapy to receive FDA approval for dystrophic epidermolysis bullosa, and its early commercialization has exceeded expectations with rapid patient adoption and strong payer acceptance. Krystal Biotech reported revenue of $389 million in 2025, and the fund expects around 30% annual revenue growth in the next few years, with GAAP operating margins rising from 42% in 2025 to 50%. The investment thesis is based on further U.S. market penetration, expansion into Europe and Japan, and the company's broad pipeline. The fund believes Krystal Biotech's first-mover advantage, strong balance sheet, and scalable platform position it to sustain leadership in rare-disease gene therapy.

Three biotech companies are approaching significant catalysts that could reshape their futures. Vera Therapeutics is preparing a Biologics License Application for atacicept, an investigational drug for IgA nephropathy, with an accelerated timeline following FDA alignment on a revised analysis plan expected in the third quarter. Krystal Biotech, which already markets the first gene therapy approved for a skin condition, anticipates top-line results from its KB803 corneal abrasion trial by year-end and a registrational data readout for KB801 in 2026. ADMA Biologics, which has multiple marketed products and reported 28% year-over-year revenue growth from ASCENIV last quarter, is advancing SG-001, an investigative hyperimmune globulin candidate for pneumococcal disease, while also benefiting from margin expansion driven by new manufacturing efficiencies.

Moderna, Krystal Biotech, and Advanced Micro Devices have significantly outperformed the broader market this year, and each still holds further upside potential. Moderna shares are up 100% year to date as the company nears potential approval for its influenza vaccine mRNA-1010 and advances a pipeline that includes a personalized cancer vaccine in phase 2 and phase 3 trials. Krystal Biotech has gained 38% this year, driven by Vyjuvek, the first FDA-approved gene therapy for dystrophic epidermolysis bullosa, with a large addressable market still untapped in Europe and elsewhere plus over half a dozen pipeline candidates. AMD has soared 129% year to date, benefiting from its leadership in server CPUs critical for agentic AI and a record 46.2% revenue share in desktop CPUs, positioning it to keep riding the AI wave.